Literature DB >> 36113467

Epstein-Barr virus: Biology and clinical disease.

Blossom Damania1, Shannon C Kenney2, Nancy Raab-Traub3.   

Abstract

Epstein-Barr virus (EBV) is a ubiquitous, oncogenic virus that is associated with a number of different human malignancies as well as autoimmune disorders. The expression of EBV viral proteins and non-coding RNAs contribute to EBV-mediated disease pathologies. The virus establishes life-long latency in the human host and is adept at evading host innate and adaptive immune responses. In this review, we discuss the life cycle of EBV, the various functions of EBV-encoded proteins and RNAs, the ability of the virus to activate and evade immune responses, as well as the neoplastic and autoimmune diseases that are associated with EBV infection in the human population.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36113467      PMCID： PMC9529843          DOI： 10.1016/j.cell.2022.08.026

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   66.850


  188 in total

1.  EBV latent membrane protein 1 is a negative regulator of TLR9.

Authors:  Ikbal Fathallah; Peggy Parroche; Henri Gruffat; Claudia Zannetti; Hanna Johansson; Jiping Yue; Evelyn Manet; Massimo Tommasino; Bakary S Sylla; Uzma A Hasan
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

2.  Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo.

Authors:  K J Gilligan; P Rajadurai; J C Lin; P Busson; M Abdel-Hamid; U Prasad; T Tursz; N Raab-Traub
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

3.  Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression.

Authors:  W E Miller; J L Cheshire; N Raab-Traub
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

Review 4.  Regulation of the latent-lytic switch in Epstein-Barr virus.

Authors:  Shannon C Kenney; Janet E Mertz
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

5.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

6.  High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia.

Authors:  Blachy J Dávila Saldaña; Tami John; Challice Bonifant; David Buchbinder; Sharat Chandra; Shanmuganathan Chandrakasan; Weni Chang; Leon Chen; Hannah L Elfassy; Ashley V Geerlinks; Roger H Giller; Rakesh Goyal; David Hagin; Shahidul Islam; Kanwaldeep Mallhi; Holly K Miller; William Owen; Martha Pacheco; Niraj C Patel; Christiane Querfeld; Troy Quigg; Nameeta Richard; Deborah Schiff; Evan Shereck; Elizabeth Stenger; Michael B Jordan; Helen E Heslop; Catherine M Bollard; Jeffrey I Cohen
Journal:  Blood Adv       Date:  2022-01-25

7.  The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.

Authors:  K M Shah; S E Stewart; W Wei; C B J Woodman; J D O'Neil; C W Dawson; L S Young
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

8.  A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis.

Authors:  Charles Torgbor; Peter Awuah; Kirk Deitsch; Parisa Kalantari; Karen A Duca; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2014-05-29       Impact factor: 6.823

9.  Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells.

Authors:  Jens S Kalchschmidt; Rachael Bashford-Rogers; Kostas Paschos; Adam C T Gillman; Christine T Styles; Paul Kellam; Martin J Allday
Journal:  J Exp Med       Date:  2016-05-23       Impact factor: 14.307

10.  EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.

Authors:  Christine T Styles; Quentin Bazot; Gillian A Parker; Robert E White; Kostas Paschos; Martin J Allday
Journal:  PLoS Biol       Date:  2017-08-03       Impact factor: 8.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.